Literature DB >> 22953654

Transoral robotic cordectomy for early glottic carcinoma.

Fatma Tülin Kayhan1, Kamil Hakan Kaya, Ibrahim Sayin.   

Abstract

OBJECTIVES: We assessed the feasibility, safety, and efficacy of transoral cordectomy performed for early glottic cancer with the da Vinci Surgical System.
METHODS: Subjects with early cancer of the vocal cords who were treated with transoral robot-assisted cordectomy were included for study. Data regarding the ability to perform robot-assisted resection, volume of blood loss,robotic operating time,pathological margin status, postoperative extubation, complications, length of hospitalization, duration until start of oral nutrition, and need for a tracheotomy were evaluated.
RESULTS: Ten men with T1 glottic carcinoma underwent successful transoral robotic cordectomy with negative margins. The mean total robotic surgery time was 21.6 +/- 6.75 minutes (range, 10 to 31 minutes). In all cases, the total blood loss was less than 20 mL. One subject needed a short-term tracheotomy and a nasogastric tube. The other 9 subjects started oral nutrition 6 to 24 hours after operation. The mean duration of hospitalization was 4.1 +/- 2.23 days.
CONCLUSIONS: Transoral robotic cordectomy with the da Vinci Surgical System was found to be feasible, relatively safe, and effective. The lower morbidity rate was an advantage of this method. Transoral robotic surgery provides better exposure, visualization, and access than does transoral laser microsurgery. Cordectomy with transoral robotic surgery should be an alternative to external-approach cordectomy and transoral laser microsurgery.

Entities:  

Mesh:

Year:  2012        PMID: 22953654     DOI: 10.1177/000348941212100801

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  13 in total

1.  Development of a new endoscope holder for head and neck surgery--from the technical design concept to implementation.

Authors:  Julia Kristin; Armin Kolmer; Peter Kraus; Robert Geiger; Thomas Klenzner
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-24       Impact factor: 2.503

Review 2.  Role of Robotics in Non-oropharyngeal Head and Neck Tumours.

Authors:  Ravi Shankar; Aseem Mishra; Akshat Malik
Journal:  Indian J Surg Oncol       Date:  2022-02-27

Review 3.  Transoral robotic cordectomy for glottic carcinoma: a rapid review.

Authors:  Jérôme R Lechien; Robin Baudouin; Marta P Circiu; Carlos M Chiesa-Estomba; Lise Crevier-Buchman; Stephane Hans
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-22       Impact factor: 3.236

Review 4.  Minimally Invasive Procedures for Laryngeal Carcinoma: Transoral Endoscopic Laser and Transoral Robotic Surgery.

Authors:  Özgül Topal
Journal:  Turk Arch Otorhinolaryngol       Date:  2017-03-01

5.  Current trends in robotic surgery for otolaryngology.

Authors:  J Kenneth Byrd; Umamaheswar Duvvuri
Journal:  Curr Otorhinolaryngol Rep       Date:  2013-09-01

6.  The First Successful Case of Transoral Robotic Surgery in a Patient with Sialadenoma Papilliferum.

Authors:  Arzu-Karaman Koç; Yakup Yegin; Mustafa Çelik; Mehmet Sar; Damlanur Sakiz; Fatma-Tülin Kayhan
Journal:  Iran J Otorhinolaryngol       Date:  2016-09

Review 7.  Evidence and evidence gaps of laryngeal cancer surgery.

Authors:  Susanne Wiegand
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

8.  Robotic microlaryngeal surgery: a new retractor that provides improved access to the glottis.

Authors:  Jennifer P Rodney; Nilesh R Vasan
Journal:  Springerplus       Date:  2016-02-27

9.  Supracricoid partial laryngectomy with crico-hyoido-epiglottopexy for glottic carcinoma with anterior commissure involvement.

Authors:  I Atallah; E Berta; A Coffre; J Villa; E Reyt; C A Righini
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-06       Impact factor: 2.124

Review 10.  A Contemporary Review of Evidence for Transoral Robotic Surgery in Laryngeal Cancer.

Authors:  Philippe Gorphe
Journal:  Front Oncol       Date:  2018-04-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.